1. Home
  2. ANAB vs CASS Comparison

ANAB vs CASS Comparison

Compare ANAB & CASS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANAB
  • CASS
  • Stock Information
  • Founded
  • ANAB 2005
  • CASS 1906
  • Country
  • ANAB United States
  • CASS United States
  • Employees
  • ANAB N/A
  • CASS N/A
  • Industry
  • ANAB Biotechnology: Pharmaceutical Preparations
  • CASS Business Services
  • Sector
  • ANAB Health Care
  • CASS Consumer Discretionary
  • Exchange
  • ANAB Nasdaq
  • CASS Nasdaq
  • Market Cap
  • ANAB 621.1M
  • CASS 567.9M
  • IPO Year
  • ANAB 2017
  • CASS 1996
  • Fundamental
  • Price
  • ANAB $23.17
  • CASS $41.36
  • Analyst Decision
  • ANAB Buy
  • CASS Buy
  • Analyst Count
  • ANAB 10
  • CASS 1
  • Target Price
  • ANAB $44.25
  • CASS $46.00
  • AVG Volume (30 Days)
  • ANAB 775.6K
  • CASS 43.9K
  • Earning Date
  • ANAB 08-04-2025
  • CASS 07-17-2025
  • Dividend Yield
  • ANAB N/A
  • CASS 2.99%
  • EPS Growth
  • ANAB N/A
  • CASS N/A
  • EPS
  • ANAB N/A
  • CASS 1.53
  • Revenue
  • ANAB $111,872,000.00
  • CASS $220,944,000.00
  • Revenue This Year
  • ANAB N/A
  • CASS N/A
  • Revenue Next Year
  • ANAB $24.39
  • CASS $7.19
  • P/E Ratio
  • ANAB N/A
  • CASS $27.44
  • Revenue Growth
  • ANAB 387.20
  • CASS 4.54
  • 52 Week Low
  • ANAB $12.21
  • CASS $37.99
  • 52 Week High
  • ANAB $41.31
  • CASS $47.14
  • Technical
  • Relative Strength Index (RSI)
  • ANAB 56.01
  • CASS 42.28
  • Support Level
  • ANAB $22.46
  • CASS $40.98
  • Resistance Level
  • ANAB $24.17
  • CASS $42.02
  • Average True Range (ATR)
  • ANAB 1.72
  • CASS 0.80
  • MACD
  • ANAB -0.01
  • CASS -0.16
  • Stochastic Oscillator
  • ANAB 73.23
  • CASS 15.97

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About CASS Cass Information Systems Inc

Cass Information Systems Inc is a provider of payment and information processing services to large manufacturing, distribution and retail enterprises across the United States. The company provides transportation invoice rating, payment processing, auditing, accounting, and transportation information. It is also a processor and payer of energy invoices, including electricity, gas, waste, and other facility-related expenses. It operates in two segments: Information Services and Banking Services. The firm generates maximum revenue from the Information Services segment, which provides transportation, energy, telecommunication, and environmental invoice processing and payment services to large corporations.

Share on Social Networks: